Category Archives: Biotechnology

Puma Biotechnology, Inc. [NASDAQ: PBYI] gained by 6.46% on the last trading session, reaching $8.90 price per share at the time. Puma Biotechnology, Inc. represents 40.21M in outstanding shares, while the company has a total market value of $336.16M with the latest information.

The Puma Biotechnology, Inc. traded at the price of $8.90 with 982313 shares were bought and sold during the latest trading session. Over the period of the last 3 months, the average trading volume of PBYI shares recorded 1.71M.

Its stock price has been found in the range of 6.26 to 43.90. This is compared to its latest closing price of $8.36.

Stay on the lookout for the next publication of this organizations financial results for the quarter, which will be made public on Thu 27 Feb (In 42 Days).

Now lets turn to look at profitability: with a current Operating Margin for Puma Biotechnology, Inc. [PBYI] sitting at -37.72 and its Gross Margin at +86.21, this companys Net Margin is now -33.90%. These metrics indicate that this company is not generating as much profit, after accounting for expenses, compared to its market peers.

This companys Return on Total Capital is -65.75, and its Return on Invested Capital has reached -55.70%. Its Return on Equity is -259.28, and its Return on Assets is -53.49. These metrics suggest that this Puma Biotechnology, Inc. does a poor job of managing its assets, and likely wont be able to provide successful business outcomes for its investors in the near term.

Turning to investigate this organizations capital structure, Puma Biotechnology, Inc. [PBYI] has generated a Total Debt to Total Equity ratio of 442.74. Similarly, its Total Debt to Total Capital is

What about valuation? This companys Enterprise Value to EBITDA is -3.57. The Enterprise Value to Sales for this firm is now 1.11, and its Total Debt to Enterprise Value stands at 0.20. Puma Biotechnology, Inc. [PBYI] has a Price to Book Ratio of 22.73.

Shifting the focus to workforce efficiency, Puma Biotechnology, Inc. [PBYI] earns $922,761 for each employee under its payroll. Similarly, this companys Receivables Turnover is 15.88 and its Total Asset Turnover is 1.18. This publicly-traded organizations liquidity data is also interesting: its Quick Ratio is 2.99 and its Current Ratio is 3.02. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

Puma Biotechnology, Inc. [PBYI] has 40.21M shares outstanding, amounting to a total market cap of $336.16M. Its stock price has been found in the range of 6.26 to 43.90. At its current price, it has moved down by -79.73% from its 52-week high, and it has moved up 42.17% from its 52-week low.

This stocks Beta value is currently 1.74, which indicates that it is 10.84% more volatile that the wider market. This stocks Relative Strength Index (RSI) is at 54.65. This RSI score is good, suggesting this stock is neither overbought or oversold.

Shares of Puma Biotechnology, Inc. [PBYI], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this companys financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.

See the rest here:
Puma Biotechnology, Inc. [PBYI] moving up 6.46% What are the long-term prospects? - The Dwinnex

Trillium Therapeutics Inc (TRIL) is near the top in its industry group according to InvestorsObserver. TRIL gets an overall rating of 93. That means it scores higher than 93 percent of stocks. Trillium Therapeutics Inc gets a 99 rank in the Biotechnology industry. Biotechnology is number 64 out of 148 industries.

Click Here to get the full Stock Score Report on Trillium Therapeutics Inc (TRIL) Stock.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Trillium Therapeutics Inc (TRIL) stock is trading at $1.32 as of 10:16 AM on Friday, Jan 3, a drop of -$0.17, or -11.4% from the previous closing price of $1.49. The stock has traded between $1.21 and $1.40 so far today. Volume today is light. So far 1,222,468 shares have traded compared to average volume of 1,841,439 shares.

To see the top 5 stocks in Biotechnology click here.

See original here:
Is Trillium Therapeutics Inc (TRIL) Stock a Good Buy in Biotechnology - InvestorsObserver

Scientists at Department of Biotechnologys Thiruvananthapuram-based Rajiv Gandhi Centre for Biotechnology have developed a new system that promises to improve the delivery of growth factors to help in healing wounds.

Wound healing is a complex process. It mainly consists of three phases - inflammation, proliferation and tissue remodeling. Application of growth factors at the site of the wound can improve the efficiency and quality of wound healing as they stimulate development of new blood vessels and proliferation of cells, which, in turn, regulates the production and degradation of the extracellular matrix.

Local application of growth factors are, however, not very effective as they have short half-life and dilute fast in the body. They also degrade quickly and become inactive due to various factors at the injury sites. Growth factors have also proved to have undesirable side effects at high systemic levels. Efforts are underway to develop ways to deliver growth factor in a controlled manner to overcome these problems.

The polymer Chitosan is being increasingly used in the treatment of wounds. Among other things, it has anti microbial properties and promotes tissue growth. However, its use in wound management is limited since it has poor mechanical properties.

In the new work, researchers at Rajiv Gandhi Centre for Biotechnology created a scaffold by cross-linking Chitosan with Polyethylene glycol (PEG), synthetic polymers. This helped to improve the strength and elasticity of Chitosan. They then conjugated the scaffold with a chemical called Heparin. This helped in the better adsorption of two growth factors -- Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (BEGF), which can be very helpful in wound healing.

In a paper published in journal, Scientific Reports, the scientists said, The efficiency of the scaffold for wound healing was tested in vitro by cell cytotoxicity assay and live/dead cell assay and in vivo by full thickness wound model. The Histology of the treated wound tissue was evaluated by H and E staining, Massons Trichrome staining, immunohistochemical staining of

Ki67 antibodies and it was found that the developed system had enhanced wound healing property.

The study was conducted by G.S.Vinod and Amritha Vijayan of Rajiv Gandhi Centre for Biotechnology, and A. Sabareeswaran of Sree Chitra Tirunal Institute for Medical Sciences & Technology, which is also based in Thiruvananthapuram.

The Rajiv Gandhi Centre for Biotechnology (RGCB) began in 1990 as a small charitable society called the Centre for Development of Education, Science and Technology. In 1991, recognizing its potential, Government of Kerala made it a "Grant-in-Aid" institute and it was renamed as Rajiv Gandhi Centre for Development of Education, Science and Technology. In 1994 the State

Government restructured it into a comprehensive biotechnology center and it was re-christened as Rajiv Gandhi Centre for Biotechnology. Later, on November 18, 2002 the then President of India, Dr A.P.J. Abdul Kalam dedicated it to the nation.

(India Science News)

Twitter handle: @ndpsr

Keywords:

Here is the original post:
New system to promote wound healing - BusinessLine

The 46 rating InvestorsObserver gives to Personalis Inc (PSNL) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 51 percent of stocks in the Biotechnology industry, PSNLs 46 overall rating means the stock scores better than 46 percent of all stocks.

Click Here to get the full Stock Score Report on Personalis Inc (PSNL) Stock.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Personalis Inc (PSNL) stock is trading at $11.39 as of 9:50 AM on Thursday, Jan 2, a rise of $0.49, or 4.5% from the previous closing price of $10.90. The stock has traded between $11.15 and $11.50 so far today. Volume today is light. So far 98,703 shares have traded compared to average volume of 479,003 shares.

To see InvestorsObserver's Sentiment Score for Personalis Inc click here.

View original post here:
Is Personalis Inc (PSNL) a Winner or a Loser in the Biotechnology Industry - InvestorsObserver

Technical Indicators of Vir Biotechnology Stock:

The share price of VIR is currently down -1.43% from its 20 days moving average and trading -5.67% declining the 50 days moving average. The stock price has been seen performing along below drift from its 200 days moving average with -6.24%. Moving averages are an important analytical tool used to identify current price trends and the potential for a change in an established trend. The simplest form of using a simple moving average in analysis is using it to quickly identify if a security is in an uptrend or downtrend.

RSI momentum oscillator is the most common technical indicator of a stock to determine about the momentum of the shares price and whether the stock trading at normal range or its becoming oversold or overbought. It also helps to measure Speed and change of stock price movement. RSI reading varies between 0 and 100. Commonly when RSI goes below 30 then stock is oversold and stock is overbought when it goes above 70. So as currently the Relative Strength Index (RSI-14) reading of Vir Biotechnology stock is 47.29.

Although it is important to look for trades in a direction of bigger trends when stocks are indicating an opposite short-term movement. Like looking for overbought conditions when bigger trend remained down and oversold conditions when bigger trend is up. In order to check a bigger trend for VIR a 14-day RSI can fell short and considered as a short-term indicator. So in that situation a Simple moving average of a stock can also be an important element to look in addition to RSI.

Looking into the Profitability indicators on Vir Biotechnology stock we analyze the stocks Profitability ratios.

Vir Biotechnology Profitability Spotlight:

Return on Investment (ROI) of stock is 66.00%. ROI ratio tells about the efficiency of a number of investments in a company.

Vir Biotechnology (VIR) Volatility Indicators:

Volatility of the Vir Biotechnology remained at 5.43% over last week and shows 6.62% volatility in last month. In addition to number of shares traded in last few trading sessions volatility also tells about the fluctuation level of the stock price, commonly a high volatility is the friend of day traders. Volatility is also measured by ATR an exponential moving average (14-days) of the True Ranges. Currently, the ATR value of companys stock is situated at 0.77.

Vir Biotechnology (VIR) has a market capitalization of $1.39B. Knowing about the market capitalization of a company helps investor to determine the company size, market value and the risk. The stock added 3.75% to value at $12.57 on Tuesday trading session. VIR recorded volume of 241429 shares in most recent trading session as compared to an average volume of 213.54K shares. It shows that the shares were traded in the recent trading session (12/31/2019) and traders shown interest in VIR stock. The stock EPS is $-1.26 against its recent stock value of $12.57 per share.

Analysts Estimation on Stock:

The current analyst consensus rating stood at 2.2 on shares (where according to data provided by FINVIZ, 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell, 5.0 Strong Sell). Analysts opinion is also an important factor to conclude a stocks trend. Many individual analysts and firms give their ratings on a stock. While Looking ahead of 52-week period, the mean Target Price set by analysts is $26.

Now entering into the performance part of the article on Vir Biotechnology stock we should check the stocks actual performance in the past.

Performance of the VIR Stock:

Vir Biotechnology revealed performance of 0.36% during the period of last 5 trading days. The stock maintained for the month at 5.23%. The stock noted year to date 2019 performance at -10.31% . The stock is now standing at -23.79% from 52 week-high and is situated at 7.94% above from 52-week low price.

View post:
Vir Biotechnology (VIR) Stock in the Investors Queue? - News Welcome

By Chris LangeJanuary 3, 2020 11:15 am

Companies in the biotech industry face an incredible amount of risk while getting their drugs to market. A study coming back negative or a candidate not being approved could crush a company. On the other hand, a positive clinical trial, or even an update from the U.S. Food and Drug Administration (FDA), could send shares skyrocketing.

On a company by company basis, this makes investing in biotechs somewhat tricky. However, there is an investment strategy that makes this process much easier.

To mitigate this risk and concern about picking the winners or the losers within the biotech (or any) industry, exchange-traded funds offer a sampling and exposure to this market without an all-or-none risk in any single companys stock. As the saying goes: Theres an ETF for that strategy. ETF Database has collected much of the information about these ETFs, among others, and made it easily accessible for those looking to get into the game. Investors can use a number of ETFs to invest in a risky biotech industry.

iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) has been around since February 2001, and it aims to track the Nasdaq Biotechnology Index. This fund seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the Nasdaq. Note that this is the largest biotech ETF, with $7.59 billion in assets under management. Its overall expense ratio is 0.47%, and it posted gains of over 22% in 2019. This ETF has a total of 218 holdings. The top 10 holdings include a mix of large-cap domestic biotech companies:

SPDR S&P Biotech ETF (NYSEARCA: XBI) has been around since February 2006 and aims to track the S&P Biotechnology Select Industry Index. This fund seeks to provide exposure to the biotechnology segment of the S&P. It has $4.37 billion in assets under management. Its overall expense ratio is 0.35%, and it traded up 30% over the course of 2019. This fund has 127 holdings. The top 10 holdings include a smattering of U.S. biotechs in the S&P 500:

First Trust NYSE Arca Biotechnology Index Fund (NYSEARCA: FBT) has been around since June 2006 and aims to track the NYSE Arca Biotechnology Index. The fund targets biopharma companies involved with recombinant DNA technology, molecular biology, genetic engineering, monoclonal antibody-based technology, lipid/liposome technology and genomics. It has $1.81 billion in assets under management, its overall expense ratio is 0.57% and it gained over 19% in 2019. This ETF has 31 holdings. The top 10 include mostly domestic biopharma firms:

VanEck Vectors Biotech ETF (NASDAQ: BBH) has been around since December 2011, and it aims to track the MVIS US Listed Biotech 25 Index. This ETF seeks to track the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment. It was last seen to have $362.6 million in assets under management. Its overall expense ratio is 0.35%, and it traded up nearly 26% in 2019. This fund has a total of 25 holdings. The top 10 holdings include mostly domestic biotech firms:

By Chris Lange

See the rest here:
The Top Biotech ETFs to Watch in 2020 - 24/7 Wall St.

The 44 rating InvestorsObserver gives to United Therapeutics Corporation (UTHR) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 43 percent of stocks in the Biotechnology industry, UTHRs 44 overall rating means the stock scores better than 44 percent of all stocks.

Click Here to get the full Stock Score Report on United Therapeutics Corporation (UTHR) Stock.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 44 means the stock is more attractive than 44 percent of stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

United Therapeutics Corporation (UTHR) stock is up 1.27% while the S&P 500 is lower by -0.07% as of 1:34 PM on Tuesday, Dec 31. UTHR is higher by $1.10 from the previous closing price of $86.91 on volume of 170,314 shares. Over the past year the S&P 500 has gained 28.41% while UTHR is lower by -19.18%. UTHR lost -$2.16 per share the over the last 12 months.

To see InvestorsObserver's Sentiment Score for United Therapeutics Corporation click here.

Go here to read the rest:
Industry Analysis: Should You Buy United Therapeutics Corporation (UTHR) in Biotechnology? - InvestorsObserver

In non-technical terms, 2019 was a weird year for biotechnology stocks and the related exchange traded funds (ETFs). For instance, the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) joined its healthcare peers in scuffling through much of the first nine months of the year, trailing broader benchmarks like the S&P 500.

The fourth quarter has been a different story. IBB, the largest biotech ETF by assets, was up 16.65% since Oct. 1, pushing its 2019 year-to-date gain to 25%. That after months of investors pulling money from actively managed biotech funds. That situation is starting to correct as well, as data out last month indicated investors are warming to biotech assets again.

There are other reasons to consider biotech ETFs with 2020 looming. Approvals from the Food & Drug Administration are coming through above the average annual rate, the valuation of large-cap biotechs are attractive, and there have been significant mergers and acquisitions in past years, according to Barrons.

With those factors in mind, lets have a look at a trio of the best biotech ETFs on the market today.

Source: Shutterstock

Expense ratio: 0.75% per year, or $75 on a $10,000 investment.

The ARK Genomic Revolution ETF (NYSEARCA:ARKG) has been immune to the aforementioned healthcare sector lethargy in 2019 as the fund went higher by almost 40%. This isnt a one-off event, either. Over the past three years, the actively managed ARKG is higher by 106.4% compared to 37.2% for the aforementioned IBB. In other words, ARKG does an excellent job of justifying its high fee.

As its name implies, ARKG isnt a standard biotech ETF. Rather, it focuses on the fast-growing genomics market, including CAR-T, CRISPR and other spaces where stock picking can be tricky for ordinary investors.

Geenomic sequencing is changing the way biological information is collected, processed, and applied. ARKG is focused on the disruptive innovations that are increasing precision, restructuring health care, agriculture, pharmaceuticals, and enhancing the quality of life, according to ARK Invest.

ARKG can hold 30 to 50 stocks and currently is home to 38, including plenty of winners, some of the very recent variety, such as Organovo (NASDAQ:ONVO).

Last Monday, Organovo jumped 24.1% after announcing it will merge with and operate as a division of Tarveda Therapeutics, said ARK. The transaction will combine Organovos proprietary 3D printingtechnology with Tarvedas proprietary Pentarin miniature drug conjugates and two clinical programs for the treatment of solid tumor malignancies.

Source: Shutterstock

Expense ratio: 0.79%

The Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC) is an under-appreciated story among biotech ETFs, but thats not preventing it from delivering jaw-dropping returns. On the back of a 28.31% gain in December, BBC closed 2019 higher by more than 62% year-to-date.

The fund benefited from a busy month for biotech companies, reports Bloomberg. While Novartiss $9.7 billion takeover of Medicines Co. boosted overall sentiment, stakes in ChemoCentryx Inc. and Karyopharm Therapeutics Inc. helped BBC outperform. ChemoCentrys shares soared on positive data regarding a drug to treat an inflammation disease, while Karyopharm reported better-than-expected sales.

This biotech ETF tracks the LifeSci Biotechnology Clinical Trials Index, which tracks the performance of select clinical trials stage biotechnology companies, according to Virtus.

Bottom line: BBC isnt for the faint of heart, but it is one of the best biotech ETFs for aggressive, risk-tolerant investors.

Source: Shutterstock

Expense ratio: 0.57%

For investors who want access to some of the biggest biotech names with a weighting methodology beyond market cap, the Invesco Dynamic Biotechnology & Genome ETF (NYSEARCA:PBE) is a practical idea.

PBE, one of the older biotech ETFs on the market, follows the Dynamic Biotech and Genome Intellidex Index. That benchmark weights its 30 components by price momentum, earnings momentum, quality, management action, and value. PBE has been effective in limiting volatility relative to legacy, equal-weight and some cap-weighted biotech ETFs.

PBEs overlap with competing funds, such as IBB, is relatively light so investors should expected substantial differences between this biotech ETF and rival products over long holding periods.

Overall, PBEs surprising lineup (its home to pharmaceuticals stocks residing in the Dow Jones Industrial Average) make this is a biotech ETF for conservative investors.

As of this writing, Todd Shriber did not own any of the aforementioned securities.

See the article here:
3 of the Best Biotech ETFs on the Market - Investorplace.com

Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the Invesco Dynamic Biotechnology & Genome ETF (PBE), a passively managed exchange traded fund launched on 06/23/2005.

An increasingly popular option among retail and institutional investors, passively managed ETFs offer low costs, transparency, flexibility, and tax efficiency; they are also excellent vehicles for long term investors.

Sector ETFs are also funds of convenience, offering many ways to gain low risk and diversified exposure to a broad group of companies in particular sectors. Healthcare - Biotech is one of the 16 broad Zacks sectors within the Zacks Industry classification. It is currently ranked 3, placing it in top 19%.

Index Details

The fund is sponsored by Invesco. It has amassed assets over $233.71 M, making it one of the average sized ETFs attempting to match the performance of the Healthcare - Biotech segment of the equity market. PBE seeks to match the performance of the Dynamic Biotechnology & Genome Intellidex Index before fees and expenses.

This is comprised of stocks of 30 U.S. biotechnology and genome companies. These are companies that are principally engaged in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes and companies that benefit significantly from scientific and technological advances in biotechnology and genetic engineering and research.

Costs

Since cheaper funds tend to produce better results than more expensive funds, assuming all other factors remain equal, it is important for investors to pay attention to an ETF's expense ratio.

Annual operating expenses for this ETF are 0.57%, making it on par with most peer products in the space.

Sector Exposure and Top Holdings

Even though ETFs offer diversified exposure which minimizes single stock risk, it is still important to look into a fund's holdings before investing. Luckily, most ETFs are very transparent products that disclose their holdings on a daily basis.

Looking at individual holdings, Biogen Inc (BIIB) accounts for about 6.28% of total assets, followed by Vertex Pharmaceuticals Inc (VRTX) and Neurocrine Biosciences Inc (NBIX).

The top 10 holdings account for about 50.41% of total assets under management.

Performance and Risk

Year-to-date, the Invesco Dynamic Biotechnology & Genome ETF has added roughly 17.18% so far, and it's up approximately 7.20% over the last 12 months (as of 11/27/2019). PBE has traded between $43.44 and $56.26 in this past 52-week period.

The ETF has a beta of 1.43 and standard deviation of 22.73% for the trailing three-year period, making it a high risk choice in the space. With about 29 holdings, it has more concentrated exposure than peers.

Alternatives

Invesco Dynamic Biotechnology & Genome ETF carries a Zacks ETF Rank of 3 (Hold), which is based on expected asset class return, expense ratio, and momentum, among other factors. Thus, PBE is a reasonable option for those seeking exposure to the Health Care ETFs area of the market. Investors might also want to consider some other ETF options in the space.

SPDR S&P Biotech ETF (XBI) tracks S&P Biotechnology Select Industry Index and the iShares Nasdaq Biotechnology ETF (IBB) tracks Nasdaq Biotechnology Index. SPDR S&P Biotech ETF has $4.20 B in assets, iShares Nasdaq Biotechnology ETF has $7.54 B. XBI has an expense ratio of 0.35% and IBB charges 0.47%.

Bottom Line

To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportInvesco Dynamic Biotechnology & Genome ETF (PBE): ETF Research ReportsiShares Nasdaq Biotechnology ETF (IBB): ETF Research ReportsSPDR S&P Biotech ETF (XBI): ETF Research ReportsVertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis ReportBiogen Inc. (BIIB) : Free Stock Analysis ReportNeurocrine Biosciences, Inc. (NBIX) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

See the original post here:
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? - Yahoo Finance

The Filipino Faces of Biotechnology award is bestowed on nine scientists, educators and science communicators during its fourth annual event held by the Department of Agriculture at a hotel in Makati on November 26.

The event is part of the weeklong National Biotechnology Week celebration. This years awardees are: Dr. Nathaniel Dugos, Outstanding researcher in bioengineering; Dr. Ernelea Cao, Outstanding educator, researcher and advocate on biotechnology; Dr. Candida Adalla, Outstanding leader in pioneering developmental initiatives for biotechnology; Dr. Gisela Concepcion, Outstanding researcher on medical and cosmetics through biotechnology; Dr. Milagros Greif, Outstanding researcher on urban pest control through biotechnology; Dr. Cynthia Hedreyda, Outstanding advocate for biotechnology education; Dr. Gabriel Romero, Outstanding researcher on rice genetics and crop biotechnology; the late Dr. Monina Villena, Outstanding science communicator for biotechnology (her husband, Nathaniel Villena, receives the award); and Dr. Claro Mingala, Outstanding livestock biotechnologist. They are joined by DA-Bureau of Agricultural Research Assistant Director Digna Sandoval (left), Agriculture Undersecretary Rodolfo Vicerra (second from right) and DA Biotechnology Program Office Director Dr. Dionisio Alvindia.

Photo by Lyn Resurreccion

Go here to see the original:
9 experts receive Faces of Biotechnology award - Business Mirror